Sharpless Says Questions Remain as FDA Moves to Streamline Insulin Approvals

Drug Industry Daily
A A
Acting FDA Commissioner Ned Sharpless said the agency is inching closer to bringing cheaper insulins to the market but that critical regulatory questions remain.

To View This Article:

Login

Subscribe To Drug Industry Daily